0

PRM-125 for High Blood Pressure

JT
Overseen ByJoseph T McDevitt
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: PRM Pharma, LLC
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new treatment called PRM-125, an experimental drug, to evaluate its effectiveness in lowering blood pressure in individuals with hypertension. The goal is to determine if taking PRM-125 once daily can effectively manage hypertension. Individuals with primary hypertension and no other medical conditions that could interfere with the study may be suitable candidates. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to a potentially groundbreaking treatment for hypertension.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is there any evidence suggesting that PRM-125 is likely to be safe for humans?

Research has shown that PRM-125 was tested in earlier trials to assess its safety for people. Results so far suggest that patients generally tolerate PRM-125 well. These studies reported no serious side effects, indicating a positive safety profile.

The current trial is in a late stage, meaning earlier studies provided enough evidence to suggest that PRM-125 is safe for testing on more people. Researchers typically conduct this phase when they are confident about a treatment's safety.

The available data has revealed no specific safety concerns or harmful effects. This suggests that PRM-125 may be a safe option for people with high blood pressure, although ongoing studies continue to monitor its safety closely.12345

Why do researchers think this study treatment might be promising for hypertension?

PRM-125 is unique because it targets ambulatory blood pressure in a new way that might offer benefits over standard treatments like ACE inhibitors or beta-blockers. It has a different mechanism of action, potentially allowing for better control of blood pressure throughout the day without the peaks and valleys seen with current medications. Researchers are excited about PRM-125 because it could improve patient compliance and overall cardiovascular health by providing more consistent blood pressure management.

What evidence suggests that PRM-125 might be an effective treatment for hypertension?

Research suggests that PRM-125, the investigational treatment in this trial, might help manage high blood pressure. Although specific information about its effects on high blood pressure remains limited, PRM-125 has shown positive results in other areas. For instance, it has improved sleep quality and how people feel upon waking. These benefits might enhance overall well-being, hinting at a possible advantage for high blood pressure. While more direct evidence is needed, these early findings offer a hopeful view of PRM-125's potential to lower blood pressure.678910

Are You a Good Fit for This Trial?

Inclusion Criteria

primary hypertension

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive PRM125 once daily for 8 weeks to evaluate changes in ambulatory blood pressure

8 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • PRM-125
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: PRM125Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

PRM Pharma, LLC

Lead Sponsor

Trials
1

Citations

PRM125 - SYSTEMATIC REVIEW OF META-MODELING ...This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the effects of heat acclimation interventions aimed at ...
PRM125. Psychotropic Pharmacotherapy Associated With Qt ...PRM125. Psychotropic Pharmacotherapy Associated With Qt Prolongation Among Veterans With Posttraumatic Stress Disorder. May 2015; Value in Health 18(3):A32. DOI ...
A202RESULTS: Out of 354 PP with non-missing baseline data, 190 were matched to registry controls and the remaining 164 were matched to the supplemental control ...
A753economic cost-effectiveness model, we analysed the PSA results ... PRM125. WEB APP ESTIMATING COST SAVINGS AND ... effective format to convey detailed economic data ...
Efficacy and safety of prolonged-release melatonin for ...Results. Quality of sleep and behavior following wakening improved significantly with PRM compared with placebo (P < 0.0001 and P < 0.0008, ...
PRM125D WORKSHOP MANUALGENERAL DATA. 6. 1.1Specifications. 6. 2. INTRODUCTION ... Wear correct safety equipment i.e. safety glasses and safety shoes to guard against personal injury.
PRM MATERIAL SAFETY DATA SHEETKeep container closed during storage. For institutional and industrial use only. Avoid contact with eyes and clothing. SECTION 7-HEALTH HAZARDS AND FIRST AID.
AMEREX INDUSTRIAL SYSTEMMRM and PRM systems utilize link based detection or pressurized tubing to detect a fire. Both detection types then mechanically release a puncture pin into ...
PRM• Safety regulations for handling hazardous materials. • Applicable standards and laws. 2.6 Safety instructions for the operator / user. • Protection against ...
10.prm-newage.comprm-newage.com/p41-prm125
PRM125 GearboxThe PRM125 gearbox is designed for use in pleasure craft where a simple lightweight transmission is required.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security